NRAS and neoplasm: The frequency of NRAS/KIT mutations and their association with patient/tumour characteristics and survival is poorly documented.<h4>Objectives</h4>To report national data from England on (i) the frequency of NRAS and KIT mutations, (ii) the association of patient/tumour characteristics with NRAS and KIT mutations, and (iii) the survival of patients with NRAS and KIT mutations.<h4>Methods</h4>This retrospective cohort study identified all new melanomas diagnosed in England from 2016 to 2021 and molecular NRAS/KIT testing using data from the National Disease Registration Service.